Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar reported Q1 revenue of $171.2 million, flat compared to the prior year, but profitability deteriorated significantly with adjusted EPS falling 43% year-over-year to $0.42. Gross margin compressed sharply from 50.0% to 41.1%, driven by lower average selling prices for key products like BAQSIMI and Glucagon, alongside increased manufacturing expenses.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.